Reported Saturday, Prelude Therapeutics Presents ASH 2025 Data Highlighting PRT12396 JAK2V617F-Selective JH2 Inhibitor And mCALR-Targeted CDK9 Degrader Antibody Conjugate In MPNs

Prelude Therapeutics, Inc. +0.29%

Prelude Therapeutics, Inc.

PRLD

3.46

+0.29%

  • First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms
  • PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026
  • First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload
  • JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of MPN patients
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.